The emerging role of estrogen in B cell malignancies

References

• Burns KA, Korach KS. Estrogen receptors and human disease: an update. Arch Toxicol. 2012;86:1491–1504.
   PubMed Web of Science ®Google Scholar
• Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265–276.
   PubMed Web of Science ®Google Scholar
• Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005;5:251–262.
   PubMed Web of Science ®Google Scholar
• Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood. 2004;103:4389–4395.
   PubMed Web of Science ®Google Scholar
• Hallek M. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015;90:446–460.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood. 2004;103:1202–1210.
   PubMed Web of Science ®Google Scholar
• Cavotsky D, Fooks J, Richards S. Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC working party on leukaemia in adults. Br J Haematol. 1989;72:141–149.
   PubMed Web of Science ®Google Scholar
• Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764–1775.
   PubMed Web of Science ®Google Scholar
• Lanham S, Hamblin T, Oscier D, et al. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood. 2003;101:1087–1093.
   PubMed Web of Science ®Google Scholar
• Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219–234.
   PubMed Web of Science ®Google Scholar
• Scupoli MT, Pizzolo G. Signaling pathways activated by the B-cell receptor in chronic lymphocytic leukemia. Expert Rev Hematol. 2012;5:341–348.
   PubMed Web of Science ®Google Scholar
• ten Hacken E, Burger JA. Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia-focus on the B-cell receptor. Clin Cancer Res. 2014;20:548–556.
   PubMed Web of Science ®Google Scholar
• Neilson JR, Auer R, White D, et al. Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival. Leukemia. 1997;11:1929–1932.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Oscier DG, Fitchett M, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med. 1990;323:720–724.
   PubMed Web of Science ®Google Scholar
• Molica S. Sex differences in incidence and outcome of chronic lymphocytic leukemia patients. Leuk Lymphoma. 2006;47:1477–1480.
   PubMed Web of Science ®Google Scholar
• Forsythe A, Breland T, Majumdar S, et al. Gender differences in incidence rates of childhood B-precursor acute lymphocytic leukemia in Mississippi. J Pediatr Oncol Nurs. 2010;27:164–167.
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Orchard JA, Davies ZA, et al. In chronic lymphocytic leukemia females survive for longer than males even in patients with unmutated immunoglobulin genes. Blood. 2004;104(11).
   Web of Science ®Google Scholar
• Everaus H. Hormones and immune responsiveness in chronic lymphocytic leukemia. Leuk Lymphoma. 1992;8:483–489.
   PubMed Web of Science ®Google Scholar
• Everaus H, Luik E, Lehtmaa J. Active and indolent chronic lymphocytic leukaemia-immune and hormonal peculiarities. Cancer Immunol Immunother. 1997;45:109–114.
   PubMed Web of Science ®Google Scholar
• Paydas S. Regression of chronic lymphocytic leukemia with aromatase inhibitor-letrozole? Leuk Res. 2009;33:566–567.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Sano M, Toi M, et al. Gan to Kagaku Ryoho. 2002;29:1211–1221.
   PubMedGoogle Scholar
• Narasimhan P. Estrogen receptor activity in Hodgkin's disease. Ann Intern Med. 1981;95:653.
   PubMed Web of Science ®Google Scholar
• Rosen ST, Maciorowski Z, Wittlin F, et al. Estrogen receptor analysis in chronic lymphocytic leukemia. Blood. 1983;62:996–999.
   PubMed Web of Science ®Google Scholar
• Zaniboni A, Di Lorenzo D, Simoncini E, et al. Estrogen and progesterone receptor guideline for tamoxifen therapy in chronic lymphocytic leukemia: a pilot study. Acta Haematol. 1986;75:92–95.
   PubMed Web of Science ®Google Scholar
• Narasimhan P, Amaral L. Lymphopenic response of patients presenting with chronic lymphocytic leukemia associated with carcinoma of the prostate to diethylstilbestrol: correlation of response to the in vitro synthesis of RNA by patient lymphocytes and its relationship to transcortin. Am J Hematol. 1980;8:369–375.
   PubMed Web of Science ®Google Scholar
• Ross JA, Sinner PJ, Blair CK, et al. Hormone replacement therapy is not associated with an increased risk of leukemia (United States). Cancer Causes Control. 2005;16:483–488.
   PubMed Web of Science ®Google Scholar
• Cerhan JR, Vachon CM, Habermann TM, et al. Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev. 2002;11:1466–1471.
   PubMed Web of Science ®Google Scholar
• Lee JS, Bracci PM, Holly EA. Non-Hodgkin lymphoma in women: reproductive factors and exogenous hormone use. Am J Epidemiol. 2008;168:278–288.
   PubMed Web of Science ®Google Scholar
• Lu Y, Wang SS, Sullivan-Halley J, et al. Oral contraceptives, menopausal hormone therapy use and risk of B-cell non-Hodgkin lymphoma in the California teachers study. Int J Cancer. 2011;129:974–982.
   PubMed Web of Science ®Google Scholar
• Mildon KH, Ansell P, Roman E, et al. Reproductive factors, menopausal hormone therapy, and risk of non-Hodgkin, diffuse large B-cell and follicular lymphomas: a UK case-control study. Cancer Causes Control. 2010;21:2079–2083.
   PubMed Web of Science ®Google Scholar
• Kane EV, Bernstein L, Bracci PM, et al. InterLymph Consortium. Postmenopausal hormone therapy and non-Hodgkin lymphoma: a pooled analysis of Interlymph case-control studies. Ann Oncol. 2013;24:433–441.
   PubMedGoogle Scholar
• Teras LR, Patel AV, Hildebrand JS, et al. Postmenopausal unopposed estrogen and estrogen plus progestin use and risk of non-Hodgkin lymphoma in the American cancer society cancer prevention study-II cohort. Leuk Lymphoma. 2013;54:720–725.
   PubMed Web of Science ®Google Scholar
• Xu X, Veenstra TD. Concentration of endogenous estrogens and estrogen metabolites in the NCI-60 human tumor cell lines. Genome Med. 2012;4:31.
   PubMed Web of Science ®Google Scholar
• Strugała AJ, Jagodziński PP. Conversion of estrone to 17 beta-estradiol in Jurkat acute T cell leukemia Hut-78 T- and Raji B lymphoma cell lines in vitro. Biomed Pharmacother. 2013;67:299–303.
   PubMed Web of Science ®Google Scholar
• Deroo BJ, Korach KS. Estrogen receptors and human disease. J Clin Invest. 2006;116:561–570.
   PubMed Web of Science ®Google Scholar
• Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer. 2011;11:597–608.
   PubMed Web of Science ®Google Scholar
• Prossnitz ER, Arterburn JB, Smith HO, et al. Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu Rev Physiol. 2008;70:165–190.
   PubMed Web of Science ®Google Scholar
• Levin ER. Plasma membrane estrogen receptors. Trends Endocrinol Metab. 2009;20:477–482.
   PubMed Web of Science ®Google Scholar
• Notas G, Kampa M, Pelekanou V, et al. Interplay of estrogen receptors and GPR30 for the regulation of early membrane initiated transcriptional effects: a pharmacological approach. Steroids. 2012; 77:943–950.
   PubMed Web of Science ®Google Scholar
• Scheller K, Sekeris CE. The effects of steroid hormones on the transcription of genes encoding enzymes of oxidative phosphorylation. Exp Physiol. 2003;88:129–140.
   PubMed Web of Science ®Google Scholar
• Psarra AM, Sekeris CE. Steroid and thyroid hormone receptors in mitochondria. IUBMB Life. 2008;60:210–223.
   PubMed Web of Science ®Google Scholar
• Chen JQ, Yager JD. Estrogen's effects on mitochondrial gene expression: mechanisms and potential contributions to estrogen carcinogenesis. Ann N Y Acad Sci. 2004;1028:258–272.
   PubMed Web of Science ®Google Scholar
• Yager JD, Chen JQ. Mitochondrial estrogen receptors-new insights into specific functions. Trends Endocrinol Metab. 2007;18:89–91.
   PubMed Web of Science ®Google Scholar
• Phiel KL, Henderson RA, Adelman SJ, et al. Differential estrogen receptor gene expression in human peripheral blood mononuclear cell populations. Immunol Lett. 2005;97:1:107–113.
   PubMed Web of Science ®Google Scholar
• Kassi EN, Vlachoyiannopoulos PG, Moutsopoulos HM, et al. Molecular analysis of estrogen receptor alpha and beta in lupus patients. Eur J Clin Invest. 2001;31:86–93.
   PubMed Web of Science ®Google Scholar
• Suenaga R, Evans MJ, Mitamura K, et al. Peripheral blood T cells and monocytes and B cell lines derived from patients with lupus express estrogen receptor transcripts similar to those of normal cells. J Rheumatol. 1998;25:1305–1312.
   PubMed Web of Science ®Google Scholar
• Nancy P, Berrih-Aknin S. Differential estrogen receptor expression in autoimmune myasthenia gravis. Endocrinology. 2005;146:2345–2353.
   PubMed Web of Science ®Google Scholar
• Rider V, Li X, Peterson G, et al. Differential expression of estrogen receptors in women with systemic lupus erythematosus. J Rheumatol. 2006;33:1093–1101.
   PubMed Web of Science ®Google Scholar
• Scariano JK, Emery-Cohen AJ, Pickett GG, et al. Estrogen receptors alpha (ESR1) and beta (ESR2) are expressed in circulating human lymphocytes. J Recept Signal Transduct Res. 2008;28:285–293.
   PubMed Web of Science ®Google Scholar
• Takao T, Kumagai C, Hisakawa N, et al. Effect of 17beta-estradiol on tumor necrosis factor-alpha-induced cytotoxicity in the human peripheral T lymphocytes. J Endocrinol. 2005;184:191–197.
   PubMed Web of Science ®Google Scholar
• Zhang J, Chen X, Zhang S, et al. Effects of transdermal estrogen therapy on expressions of estrogen receptors and T-lymphocyte apoptosis in surgically menopausal women. Cell Mol Immunol. 2009;6:277–283.
   PubMed Web of Science ®Google Scholar
• Stygar D, Westlund P, Eriksson H, et al. Identification of wild type and variants of oestrogen receptors in polymorphonuclear and mononuclear leucocytes. Clin Endocrinol (Oxf). 2006;64:74–81.
   PubMed Web of Science ®Google Scholar
• Pierdominici M, Maselli A, Colasanti T, et al. Estrogen receptor profiles in human peripheral blood lymphocytes. Immunol Lett. 2010;132:79–85.
   PubMed Web of Science ®Google Scholar
• Shim GJ, Gherman D, Kim HJ, et al. Differential expression of oestrogen receptors in human secondary lymphoid tissues. J Pathol. 2006;208:408–414.
   PubMed Web of Science ®Google Scholar
• Iacobelli S, Natoli V, Longo P, et al. Glucocorticoid receptor determinations in leukemia patients using cytosol and whole-cell assays. Cancer Res. 1981;41:3979–3984.
   PubMed Web of Science ®Google Scholar
• Melo N, Hobday C, Dowsett M, et al. Oestrogen receptor (ER) analysis in B-cell chronic lymphocytic leukemia: correlation of biochemical and immunocytochemical methods. Leuk Res. 1990;14:949–952.
   PubMed Web of Science ®Google Scholar
• Nishikawa M, Uemura Y, Komada F, et al. Clinical response to busramustine (KM-2210) in chronic lymphocytic leukemia: a pilot evaluation of estrogen receptor in relation to its therapeutic effect. Jpn J Clin Oncol. 1988;18:327–333.
   PubMed Web of Science ®Google Scholar
• Yakimchuk K, Norin S, Kimby E, et al. Up-regulated estrogen receptor β2 in chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53:139–144.
   PubMed Web of Science ®Google Scholar
• Yakimchuk K, Iravani M, Hasni MS, et al. Effect of ligand-activated estrogen receptor β on lymphoma growth in vitro and in vivo. Leukemia. 2011;25:1103–1110.
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Meilus S, Rodriguez J, et al. Endocrine characterization of primary mediastinal lymphoma. Leuk Lymphoma. 1996;23:613–615.
   PubMed Web of Science ®Google Scholar
• Yakimchuk K, Hasni MS, Guan J, et al. Inhibition of lymphoma vascularization and dissemination by estrogen receptor β agonists. Blood. 2014;123:2054–2061.
   PubMed Web of Science ®Google Scholar
• Issa JP, Zehnbauer BA, Civin CI, et al. The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Cancer Res. 1996;56:973–977.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Daniel J, Smith TL, et al. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res. 2002;8:2217–2224.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Faderl S, O'Brien S, et al. Chronic myelogenous leukemia: a review and update of therapeutic strategies. Cancer. 2003;98:437–457.
   PubMed Web of Science ®Google Scholar
• Hess CJ, Errami A, Berkhof J, et al. Concurrent methylation of promoters from tumor associated genes predicts outcome in acute myeloid leukemia. Leuk Lymphoma. 2008;49:1132–1141.
   PubMed Web of Science ®Google Scholar
• Agrawal S, Unterberg M, Koschmieder S, et al. DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia. Cancer Res. 2007;67:1370–1377.
   PubMed Web of Science ®Google Scholar
• Garzon R, Liu S, Fabbri M, et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood. 2009;113:6411–6418.
   PubMed Web of Science ®Google Scholar
• Jamroziak K, Smolewski P, Cebula B, et al. Relation of P-glycoprotein expression with spontaneous in vitro apoptosis in B-cell chronic lymphocytic leukemia. Neoplasma. 2004;51:181–187.
   PubMed Web of Science ®Google Scholar
• McMurray RW, Suwannaroj S, Ndebele K, et al. Differential effects of sex steroids on T and B cells: modulation of cell cycle phase distribution, apoptosis and bcl-2 protein levels. Pathobiology. 2001;69:44–58.
   PubMed Web of Science ®Google Scholar
• Batsi C, Markopoulou S, Kontargiris E, et al. Bcl-2 blocks 2-methoxyestradiol induced leukemia cell apoptosis by a p27(Kip1)-dependent G1/S cell cycle arrest in conjunction with NF-kappaB activation. Biochem Pharmacol. 2009;78:33–44.
   PubMed Web of Science ®Google Scholar
• Paietta E, Tudoriu CD, Goldstein M, et al. Plasmacytoid blast crisis in B-cell chronic lymphocytic leukemia: effect of estradiol on growth and differentiation in vitro. Leuk Res. 1985;9:19–29.
   PubMed Web of Science ®Google Scholar
• Grimaldi CM, Cleary J, Dagtas AS, et al. Estrogen alters thresholds for B cell apoptosis and activation. J Clin Invest. 2002;109:1625–1633.
   PubMed Web of Science ®Google Scholar
• Fu Y, Li L, Liu X, et al. Estrogen promotes B cell activation in vitro through down-regulating CD80 molecule expression. Gynecol Endocrinol. 2011;27:593–596.
   PubMed Web of Science ®Google Scholar
• Lee J, Shin EK, Lee SY, et al. Estrogen upregulates IL-21 production by CD4+ T lymphocytes in patients with systemic lupus erythematosus. Immunology. 2014;142:573–580.
   PubMed Web of Science ®Google Scholar
• Bodhankar S, Wang C, Vandenbark AA, et al. Estrogen-induced protection against experimental autoimmune encephalomyelitis is abrogated in the absence of B cells. Eur J Immunol. 2011;41:1165–1175.
   PubMed Web of Science ®Google Scholar
• Bodhankar S, Vandenbark AA, Offner H. Oestrogen treatment of experimental autoimmune encephalomyelitis requires 17β-oestradiol-receptor-positive B cells that up-regulate PD-1 on CD4+ Foxp3+ regulatory T cells. Immunology. 2012;137:282–293.
   PubMed Web of Science ®Google Scholar
• Scrivener S, Goddard RV, Kaminski ER, et al. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma. 2003;44:38338–38339.
   Web of Science ®Google Scholar
• Hill L, Jeganathan V, Chinnasamy P, et al. Differential roles of estrogen receptors α and β in control of B-cell maturation and selection. Mol Med. 2011;17:211–220.
   PubMed Web of Science ®Google Scholar
• Vasanwala FH, Kusam S, Toney LM, et al. Repression of AP-1 function: a mechanism for the regulation of Blimp-1 expression and B lymphocyte differentiation by the B cell lymphoma-6 protooncogene. J Immunol. 2002;169:1922–1929.
   PubMed Web of Science ®Google Scholar
• Pauklin S, Sernández IV, Bachmann G, et al. Estrogen directly activates AID transcription and function. J Exp Med. 2009;206:99–111.
   PubMed Web of Science ®Google Scholar
• Mai T, Zan H, Zhang J, et al. Estrogen receptors bind to and activate the HOXC4/HoxC4 promoter to potentiate HoxC4-mediated activation-induced cytosine deaminase induction, immunoglobulin class switch DNA recombination, and somatic hypermutation. J Biol Chem. 2010;285:37797–37810.
   PubMed Web of Science ®Google Scholar
• Weisz A, Rosales R. Identification of an estrogen response element upstream of the human c-fos gene that binds the estrogen receptor and the AP-1 transcription factor. Nucleic Acids Res. 1990;18:5097–5106.
   PubMed Web of Science ®Google Scholar
• Ambrosino C, Cicatiello L, Cobellis G, et al. Functional antagonism between the estrogen receptor and Fos in the regulation of c-fos protooncogene transcription. Mol Endocrinol. 1993;7:1472–1483.
   PubMed Web of Science ®Google Scholar
• Mandal S, Davie JR. Estrogen regulated expression of the p21 Waf1/Cip1 gene in estrogen receptor positive human breast cancer cells. J Cell Physiol. 2010;224:28–32.
   PubMed Web of Science ®Google Scholar
• Dong L, Wang W, Wang F, et al. Mechanisms of transcriptional activation of bcl-2 gene expression by 17beta-estradiol in breast cancer cells. J Biol Chem. 1999;274:32099–32107.
   PubMed Web of Science ®Google Scholar
• Duplessis TT, Williams CC, Hill SM, et al. Phosphorylation of Estrogen Receptor α at serine 118 directs recruitment of promoter complexes and gene-specific transcription. Endocrinology. 2011;152: 2517–2526.
   PubMed Web of Science ®Google Scholar
• Berger CE, Qian Y, Liu G, et al. p53, a target of estrogen receptor (ER) α, modulates DNA damage-induced growth suppression in ER-positive breast cancer cells. J Biol Chem. 2012;287:30117–30127.
   PubMed Web of Science ®Google Scholar
• Rasti M, Arabsolghar R, Khatooni Z, et al. p53 Binds to estrogen receptor 1 promoter in human breast cancer cells. Pathol Oncol Res. 2012;18:169–175.
   PubMed Web of Science ®Google Scholar
• Wiestner A. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. Haematologica. 2015;100:1495–1507.
   PubMed Web of Science ®Google Scholar
• Carew JS, Zhou Y, Albitar M, et al. Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications. Leukemia. 2003;17:1437–1447.
   PubMed Web of Science ®Google Scholar